^
Association details:
| Biomarker: | MET exon 14 mutation + EGFR exon 20 insertion |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report
Published date:
04/07/2021
Excerpt:
...33-year-old NSCLC patient with a germline MET exon 14 skipping mutation, who also harbored a somatic EGFR exon 20 insertion. The patient was initially diagnosed with a stage IIB adenosquamous carcinoma....anlotinib but did not respond and died a month later with an overall survival of 9 months.
DOI:
https://doi.org/10.2147/OTT.S295542
